Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

Online download statistics by month:

Online download statistics by month: March 2022 to March 2024

	Abstract	Full	Pdf
Mar 2022	442	458	227
Apr 2022	242	249	115
May 2022	184	188	72
Jun 2022	162	165	48
Jul 2022	132	135	44
Aug 2022	205	206	57
Sep 2022	157	162	53
Oct 2022	172	176	56
Nov 2022	152	152	56
Dec 2022	131	133	51
Jan 2023	80	80	24
Feb 2023	80	82	41
Mar 2023	54	54	45
Apr 2023	53	55	32
May 2023	52	53	29
Jun 2023	47	47	17
Jul 2023	45	45	29
Aug 2023	52	52	27
Sep 2023	39	39	27
Oct 2023	42	42	19
Nov 2023	68	68	27
Dec 2023	67	68	49
Jan 2024	73	73	56
Feb 2024	59	59	43
Mar 2024	55	55	78
Total	2845	2896	1322